The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the intensifying legal battles over modern vaccine technologies, Sanofi has filed federal lawsuits in the US against Moderna and Pfizer seeking patent royalties. Sanofi alleges that COVID-19 and RSV vaccines produced by its competitors infringe on up to 10 mRNA delivery patents held by its unit, Translate Bio. The French pharmaceutical giant is seeking compensation for the proprietary technology used in the Spikevax, Comirnaty, and mResvia vaccines.
This dispute emerges as mRNA vaccine sales normalize post-pandemic; for context, Pfizer reported Comirnaty revenues of $11.2 billion in 2023, a significant drop from pandemic peaks according to annual filings. Per market data, SNY closed at $43.18, while PFE stood at $24.25 and MRNA at $67.44 (close of July 14, 2026). This litigation is part of a broader industry trend where mega-cap pharma companies are increasingly contesting the intellectual property that underpinned the rapid global vaccine rollout.
Investors should watch for legal proceedings in the US District Court of New Jersey, as any court-ordered royalties or settlements could provide a windfall for Sanofi at the expense of Moderna and Pfizer's margins. Based on closing levels on July 14, 2026, SNY is trading near its daily high of $43.45, suggesting a positive market reception to the claim. With no major sector-specific catalysts in the immediate economic calendar, the focus remains on the formal legal responses from the defendants.